Low-dose intestinal radiation plus immunotherapy for immune-resistant metastatic solid cancers
Official title: Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy and PD-1/PD-L1 Inhibitors for Metastatic Malignant Solid Tumors After Acquired Resistance to Anti-PD1/PD-L1 Treatment
Run by Shantou University Medical College · NCT07071103 · Data updated 2026-11-12
This trial tests whether giving small doses of radiation to the intestine together with PD‑1/PD‑L1 immunotherapy can help people whose metastatic solid tumors have stopped responding to checkpoint inhibitors.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 48 (estimated) |
| Sponsor | Shantou University Medical College Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Shantou, Guangdong) |
| Status | Recruiting |
| Started | September 26, 2025 |
| Main results expected | January 1, 2028 |
| Study ends | January 1, 2028 |
| Registry record updated | November 20, 2025 |
| Trial ID | NCT07071103 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (18–80) with metastatic solid tumors that have progressed on prior PD‑1/PD‑L1 therapy, have at least one measurable lesion, ECOG performance status 0–2, and no standard treatment options remaining.
✕Probably not a fit
Patients with poor performance status (ECOG >2), life expectancy under three months, those who remain candidates for standard surgical or systemic treatments, or those unable to attend the single study site are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicohort phase II trial combining intestinal low‑dose radiotherapy (ILDR) with PD‑1/PD‑L1 monoclonal antibody therapy in patients with metastatic solid tumors that progressed after prior checkpoint inhibitor treatment. Patients are enrolled into three parallel cohorts (lung cancer, esophageal cancer, and other solid tumors) with up to 16 patients per cohort and a planned total of 48 participants including those from the prior ILDR‑01 study. The trial delivers targeted low doses of radiation to the intestine to alter the gut microenvironment and immune signaling while continuing systemic PD‑1/PD‑L1 therapy, and monitors safety and antitumor activity by RECIST and clinical follow‑up. Eligible patients are adults (18–80) with ECOG 0–2, measurable disease, life expectancy ≥3 months, and no remaining standard treatment options.
Why it matters
Potential benefit: If successful, the combination could re‑sensitize resistant tumors to immunotherapy, producing tumor shrinkage or slower disease progression for patients who had stopped responding to checkpoint inhibitors.
How similar studies have gone: Preclinical data and small clinical reports indicate low‑dose radiation can modulate immunity and enhance checkpoint blockade, but large randomized evidence specifically for intestinal low‑dose radiotherapy combined with PD‑1/PD‑L1 inhibitors is currently lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years, ≤80 years, regardless of gender. * ECOG level 0-2. * Expected life span\>3 months. * At least one accessible and measurable lesion should be selected as the target lesion for observation according to RECIST criteria. * Patients with metastatic solid tumors (of any histology) without standard therapy options, who have previously received immunotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with anti-angiogenesis treatment and have shown disease progression. * Patients should not be considered eligible for surgical treatment. * Patients with brain metastases that are assessed as clinically stable after treatment through repeated CT and/or MRI scans are eligible. * Patients have complete clinical and pathological information. * Patients should not be borthered by any psychological, family, social or geographical conditions that may hinder compliance with the research protocol. * Patients should be able to understand the informed consent form, voluntarily participate, and sign the informed consent form. * Other indicators accord with the general inclusion criteria for clinical trials. Exclusion Criteria: * Patients with contraindications to radiation therapy and immunotherapy. * Previous occurrence of unacceptable immune related toxic side effects (immune myocarditis, pneumonia, etc.). * Patients who were assessed as hyperprogressive disease (HPD). * Patients who have received pelvic and abdominal radiation therapy within 6 months prior to enrollment. * The adverse reactions from prior treatment have not yet recovered to a CTCAE5.0 rating of ≤ 1 (excluding toxicity that has been determined to be risk-free, such as fatigue or hair loss). * Patients with active uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment. * Significant liver or kidney dysfunction (i.e., laboratory values \>3 times the upper limit of normal). * Active hepatitis B, hepatitis C, HIV, or syphilis. * Brain disorders, symptomatic central nervous system (CNS) or meningeal metastases, or impaired cognitive function. * Hypersensitivity to any drug included in the trial. * Drug and/or alcohol abuse. * Pregnant or breastfeeding women. * Concurrent participation in another therapeutic clinical trial. * Poorly controlled pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within ≤14 days after intervention). * Major surgery within 30 days. * Use of antibiotics, antifungals, antivirals, antiparasitics, or probiotics within 4 weeks before enrollment.
Where it's running
-
Cancer Hospital, Shantou University Medical College
Shantou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Chuangzhen Chen, MD
- Email: czchen2@stu.edu.cn
- Phone: +86 13923995569
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Analysis of outcomes and side effects in patients receiving radiation therapy
This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.
-
Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread
This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Tributyrin as a dietary supplement to help prevent radiation-induced rectal injury during rectal cancer chemoradiation
This study tests whether adding tributyrin to standard chemoradiotherapy helps prevent acute radiation-induced rectal injury in people with locally advanced rectal cancer.
-
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC
This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.
-
Virtual vs in-person follow-up visits after radiotherapy
This study tests whether telehealth follow-ups during radiotherapy are practical and satisfactory for patients and physicians, compared to in-person visits.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.